| 05.05.23 | Lilly's anticipated Alzheimer's data shows slowing cognitive decline; Merck entitled to $1.4B in cyberattack case, court says

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

1 jahr vor

Html
Text

Weekly Digest

Learn fresh ideas around data, tech, and analytics

Attend Fusion 2023, a free virtual conference. Whether your involvement is in brand, commercial tech, sales operations, or adjacent roles, these sessions are designed to provide fresh ideas and provoke critical thinking around data, tech, and analytics. Register now!

This Week

May 5, 2023

Lilly's hotly anticipated Alzheimer's data set a new high score in slowing cognitive decline

Merck entitled to $1.4B in cyberattack case after court rejects insurers' 'warlike action' claim

The top 10 pharma drug ad spenders for 2022

Pfizer kicks newly acquired meds out of Arena as part of midstage cleaning

GSK staffers kick off series of strikes in UK for the first time in drugmaker's history

With negative FDA panel vote, AZ and Merck's Lynparza looks set for narrow nod in prostate cancer

Dexcom sets new user records in first quarter following G7 kickoff

Dual CRISPR therapy plus long-acting ART eliminates HIV in mice

J&J refuels CAR-T ambitions with $245M upfront to Cellular Biomedicine for pair of therapies

Labeling error forces Teva to recall 13 lots of fentanyl buccal tablets

Something in the water? 2 biotechs cast off old names as they shore up new identities

Utilizing an automated bio-decontamination process can help reduce the risk of a microbial contamination. Ecolab’s Bioquell offering has solutions to provide validated and repeatable results for equipment, pass-throughs, zones, and more. Learn more.

Featured

Lilly's hotly anticipated Alzheimer's data set a new high score in slowing cognitive decline

By Annalee Armstrong

Eli Lilly’s Alzheimer’s disease candidate has achieved a 35% slowing of cognitive decline and a 39% lower risk of advancing to the next stage of the disease when compared to placebo.

Merck entitled to $1.4B in cyberattack case after court rejects insurers' 'warlike action' claim

By Angus Liu

A New Jersey appellate court ruled that a group of insurers can’t use war as an argument to deny Merck coverage from the notorious NotPetya cyberattack in 2017.

The top 10 pharma drug ad spenders for 2022

By Ben Adams

Welcome to the breakdown of the top 10 biggest drug ad spenders in pharma for 2022 as we reveal who funneled the most cash into their campaigns.

Pfizer kicks newly acquired meds out of Arena as part of midstage cleaning

By Max Bayer

Pfizer is axing a handful of midstage medicines, most of which stemmed from the company's acquisition of Arena Pharmaceuticals. Company executives also noted on its first-quarter earnings call that it remains on the M&A hunt even after acquiring Seagen for almost $50 billion.


A message from Digital Pharma Innovation Week

GSK staffers kick off series of strikes in UK for the first time in drugmaker's history

By Angus Liu

Workers at GSK’s Montrose facility in Scotland on Tuesday kicked off a series of strikes that will sequentially affect six of the company’s sites and last throughout May.

With negative FDA panel vote, AZ and Merck's Lynparza looks set for narrow nod in prostate cancer

By Angus Liu

A panel of external experts for the FDA voted 11 to 1 in support of a narrow approval for AstraZeneca and Merck's Lynparza in metastatic castration-resistant prostate cancer (mCRPC). A comment from FDA's oncology chief Rick Pazdur, M.D., likely played a crucial part in Friday's vote outcome.

Dexcom sets new user records in first quarter following G7 kickoff

By Conor Hale

After collecting a long-awaited FDA clearance for the latest generation of its wearable continuous glucose monitor last December, Dexcom has offered a peek into the momentum behind its G7 diabetes sensor.

Dual CRISPR therapy plus long-acting ART eliminates HIV in mice

By Helen Floersh

The scientists who used CRISPR to eliminate HIV in mice have done it again, this time with a three-pronged approach that nearly doubled their success rate.

J&J refuels CAR-T ambitions with $245M upfront to Cellular Biomedicine for pair of therapies

By James Waldron

Johnson & Johnson may have gone quiet on getting further CAR-Ts into the clinic beyond the success of its Legend-partnered Carvykti, but that’s about to change.

Labeling error forces Teva to recall 13 lots of fentanyl buccal tablets

By Kevin Dunleavy

A labeling problem has forced Teva to recall 13 lots of fentanyl buccal tablets. Safety updates on the product insert were omitted, leaving the possibility of misuse that “could lead to life-threatening adverse events,” the FDA said.

Something in the water? 2 biotechs cast off old names as they shore up new identities

By Ben Adams

Two biotechs are making their old selves walk the plank as they take on new names in the hopes of a bounteous future.

Fierce podcasts

Don't miss an episode

'The Top Line': Part 2 of a series on Narcan, the life-saving nasal spray

This week on "The Top Line," we're continuing our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription.

'The Top Line': A special series on Narcan, the life-saving nasal spray

'Podnosis': Healthcare’s relationship to climate change


A message from Digital Pharma Engage

Resources

Whitepaper

Discover a New Way to Measure Potency for Gene Therapy Protein Expression

Discover the new gold standard for gene therapy protein expression potency measurements.

Decentralized Clinical Trials: The Complete Guide for 2023

Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success.

How Lilly’s Legal and Library Services Empower Teams Across the Drug Development Pipeline

What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how.

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.

Sponsored by: Blue Matter, strategic consultants in the life sciences

Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.

Sponsored by: Thermo Scientific Production Chemicals and Services

Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.